We first examined the glioblastoma immunopeptidomes of 19 patients for HLA class II-bound bacterial peptides, and next whether TILs and TIL-derived CD4+ T cell clones (TCCs) in one of the patients react against HLA-bound bacterial peptides and tumour antigens. This evidence concerns the gene CD4 and glioblastoma.